Long-Term Prolonged-Release Fampridine Treatment and Quality of Life
An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Sclerosis
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
Change from baseline in the PCS of the SF-36 measured over Months 3, 6, 9, and 12 among subjects who respond to treatment with prolonged-release fampridine.
Quality of life (reported by participants)
Other measures (1)
1)Comparison of the change from baseline in the PCS of the SF-36 measured over Months 3, 6, 9, and 12 among subjects who respond to treatment with prolonged-release fampridine and those who do not.
Quality of life (reported by participants)
Loading reviews and guidelines…
Related trials
- Dalfampridine Combined With Physical Therapy for Mobility Impairment i
Phase 3 · Recruiting
Still running
- Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthal
Phase 3 · Stopped early
Stopped: not working
- New strategies for diagnostic, therapeutic and clinical care in neurol
Phase 4 · Status unknown
No results found
- Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Sp
Not a drug-phase study · Completed
Paper found, not read
- Fampridine in MS Patients: A Cognition, Fatigue, Depression and Qualit
Completed
Paper found, not read
- Effects of dalfampridine on mobility in the context of daily life
Phase 4 · Completed
No results found
History
- In scope changed from true to false
Started
Oct 2011